Certified by Founder
Lodge
AstronauTx
start up
United Kingdom
- London, England
- 09/10/2023
- Series A
- $58,462,000
AstronauTx is at the forefront of a novel approach to treating neurodegenerative diseases. We have a unique portfolio of small-molecule therapeutics to restore dysregulated physiology to both improve symptoms and modify disease.
- Industry Biotechnology Research
- Website https://astronautx.bio/
- LinkedIn https://www.linkedin.com/company/astronautx/about/